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Ultra-Rare Genetic Variation in the Epilepsies:
A Whole-Exome Sequencing Study of 17,606 Individuals
Epi25 Collaborative*,*
Sequencing-based studies have identified novel risk genes associatedwith severe epilepsies and revealed an excess of rare deleterious vari-
ation in less-severe forms of epilepsy. To identify the shared and distinct ultra-rare genetic risk factors for different types of epilepsies, we
performed a whole-exome sequencing (WES) analysis of 9,170 epilepsy-affected individuals and 8,436 controls of European ancestry.We
focused on three phenotypic groups: severe developmental and epileptic encephalopathies (DEEs), genetic generalized epilepsy (GGE),
and non-acquired focal epilepsy (NAFE). We observed that compared to controls, individuals with any type of epilepsy carried an excess
of ultra-rare, deleterious variants in constrained genes and in genes previously associated with epilepsy; we saw the strongest enrichment
in individuals with DEEs and the least strong in individuals with NAFE. Moreover, we found that inhibitory GABAA receptor genes were
enriched for missense variants across all three classes of epilepsy, whereas no enrichment was seen in excitatory receptor genes. The
larger gene groups for the GABAergic pathway or cation channels also showed a significant mutational burden in DEEs and GGE.
Although no single gene surpassed exome-wide significance among individuals with GGE or NAFE, highly constrained genes and genes
encoding ion channels were among the lead associations; such genes included CACNA1G, EEF1A2, and GABRG2 for GGE and LGI1,
TRIM3, and GABRG2 for NAFE. Our study, the largest epilepsy WES study to date, confirms a convergence in the genetics of severe
and less-severe epilepsies associated with ultra-rare coding variation, and it highlights a ubiquitous role for GABAergic inhibition in ep-
ilepsy etiology.Introduction
Epilepsy is a group of disorders characterized by repeated
seizures caused by excessive electrical activity in the brain
and is one of the most common neurological conditions;
epilepsy affects 5–7 of every 1,000 individuals world-
wide.1,2 Human genetics research has established that a
genetic basis contributes to the susceptibility to epilepsy
for a majority of the cases.3–6 However, the multifactorial
condition of epilepsy that subsumes a variety of epilepsy
types, seizures, levels of severity, and comorbidity has
made it a core challenge to disentangle the genetic
architecture for different types of epilepsy and to deter-
mine the specific genetic risks for each individual with
epilepsy.
In recent years, our understanding of the genetic risk fac-
tors for epilepsy has substantially expanded thanks to the
rapid advancement in sequencing technology. Currently,
gene identification from sequencing-based studies has
been primarily limited to rare, monogenic forms of epi-
lepsy, and much of the focus has been on a group of severe
epilepsy syndromes known as the developmental and
epileptic encephalopathies (DEEs [MIM: 308350]).7–11
DEEs typically begin early in life and are characterized by
intractable seizures and profound to mild developmental
impairment. It was found that one in every 2,000 infants
develops severe epilepsy with onset under 18 months.12
For these severe epilepsies, dozens of genes with de novo
pathogenic variants have been identified, and the number
continues to grow. The other major epilepsy types broadly
encompass genetic generalized epilepsy (GGE [MIM:
600669]) and non-acquired focal epilepsy (NAFE [MIM:*Correspondence: s.berkovic@unimelb.edu.au, bneale@broadinstitute.org
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involving both hemispheres of the brain, the latter a local-
ized cortical region. The incidence of these groups is not
well established, but they are recognized as the more-com-
mon, less-severe forms of epilepsy, and epidemiological
studies have estimated that generalized and focal epilepsies
each account for 20%–40% of incident epilepsies.13–16 As
with DEEs, there are several specific electroclinical syn-
dromes within the classes of GGE and NAFE, but the ge-
netic etiology is more complex. Genetic investigations
into GGE or NAFE thus far both support both a role for
an oligogenic or polygenic component17–20 and provide
some evidence for monogenic causes for a minority of
affected individuals.5 Despite a significant heritability
consistently demonstrated from twin, family, and
genome-wide association studies (GWAS),4,19–22 the dis-
covery of individual genes associated with GGE and
NAFE has remained scarce. Most genes identified to date
come from monogenic families of focal epilepsies, and at-
tempts to identify risk genes associated with GGE have
been largely unsuccessful.23–25 For most of the GGE- and
NAFE-affected individuals with non-familial onsets, the
specific pathogenic variants are not yet known, and gene
findings from small-scale studies have often not been
reproducible.26–28
Two recent whole-exome sequencing (WES) case-control
studies leveraged hundreds of familial cases and provided
clear evidence of specific gene groups linked to the risk of
GGE and NAFE.24,25 Specifically, the authors showed that
ultra-rare genetic variation in genes associated with DEEs
was enriched in GGE and NAFE and that enrichment of
missense variants in all genes encoding GABAA receptorsAmerican Journal of Human Genetics 105, 1–16, August 1, 2019 1
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highlight that genes commonly implicated in epilepsy
can span a wider range of epilepsy phenotypes than previ-
ously postulated. Studying rare genetic variation involving
severe to milder electroclinical syndromes of epilepsy
can help researchers to better understand the extent
of phenotypic pleiotropy and variable expressivity that
could inform treatment strategies. On the other hand,
the extensive phenotypic and genetic heterogeneity
of epilepsy, especially for GGE and NAFE, underscores
the need to enlarge the scale of such studies beyond famil-
ial cases.
Here, we evaluate a WES case-control study of epilepsy
from the Epi25 Collaborative—an ongoing global effort
to collect an unprecedented number of patient cohorts pri-
marily for the three major classes of non-lesional epi-
lepsies: DEEs, GGE, and NAFE.29 We aimed to pinpoint
the distinct and overlapping genetic risk of ultra-rare cod-
ing variants for these different phenotypic groups by eval-
uating the burden at the individual gene level and in
candidate gene sets in order to understand the role of
rare genetic variation and identify specific associated genes
across the severity spectrum for epilepsy syndromes.Material and Methods
Study Design and Participants
We collectedDNA from and detailed phenotyping data on individ-
uals with epilepsy from 37 sites in Europe, North America, Austral-
asia, and Asia (see Supplemental Data and Table S1). Here we
analyzed subjects with GGE (also known as idiopathic generalized
epilepsy; n ¼ 4,453), NAFE (n ¼ 5,331), and DEEs (n ¼ 1,476); and
a small number of other epilepsies were also included in the initia-
tive (Table S1). A subset of the data is available on dbGaP:
phs001489. Control samples were aggregated from local collec-
tions at the Broad Institute or obtained from dbGaP, and these
controls consisted of 17,669 individuals of primarily European
ancestry who were not screened for neurological or neuropsychi-
atric conditions (see Table S2 and Supplemental Data).
Phenotyping Procedures
Epilepsies were diagnosed by experienced epileptologists on clin-
ical grounds based on the criteria given in the next paragraph
(see below for criteria GGE, NAFE, and DEEs, respectively) and
consistent with International League Against Epilepsy (ILAE) clas-
sification at the time of diagnosis and recruitment. De-identified
(non-PHI [protected health information]) phenotyping data were
entered into the Epi25 Data repository (hosted at the Luxembourg
Centre for Systems Biomedicine) via detailed online case record
forms based on the RedCAP platform. Where subjects were part
of previous coordinated efforts with phenotyping on databases
(e.g., the Epilepsy Phenome/Genome Project30 and the EpiPGX
project [Web Resources]), deidentified data were accessed and
transferred to the new platform. Phenotyping data underwent re-
view for uniformity among sites and quality control (QC) by auto-
mated data checking, followed by manual review if required.
Where doubt remained about eligibility, cases were reviewed by
the phenotyping committee, and sometimes further data were re-
quested from the source site before a decision was made.2 The American Journal of Human Genetics 105, 1–16, August 1, 201Case Definitions
Diagnosis of GGE required a convincing history of generalized
seizure types (generalized tonic-clonic, absence, or myoclonic sei-
zures) and generalized epileptiform discharges on EEG. We
excluded cases with evidence of focal seizures or with moderate-
to-severe intellectual disability and those with an epileptogenic
lesion found on neuroimaging (although neuroimaging was not
obligatory). If a diagnostic source EEG was not available, then
only cases with archetypal clinical histories as judged by the phe-
notyping committee (e.g., morning myoclonus and generalized
tonic-clonic seizures for a diagnosis of juvenile myoclonic epi-
lepsy) were accepted.
Diagnosis of NAFE required a convincing history of focal sei-
zures; an EEG with focal epileptiform or normal findings (since
routine EEGs are often normal in focal epilepsy); and neuroimag-
ing showing no epileptogenic lesion except hippocampal scle-
rosis. (MRI was preferred, but CT was accepted.) Exclusion criteria
were a history of generalized onset seizures or moderate-to-severe
intellectual disability.
The DEE group was comprised of subjects with severe refractory
epilepsy of unknown etiology, with developmental plateau or
regression, with no epileptogenic lesion on MRI, and with epilep-
tiform features found on EEG. Because this is the group with the
largest number of gene discoveries to date, we encouraged inclu-
sion of those with non-explanatory epilepsy gene panel results,
but we did not exclude those who had not undergone prior testing
(Table S7).
Informed Consent
Adult subjects, or in the case of children, their legal guardians, pro-
vided signed informed consent at the participating centers accord-
ing to local national ethical requirements. Samples had been
collected over a 20 year period in some centers, so the consent
forms reflected standards at the time of collection. Samples were
only accepted if the consent did not exclude data sharing. For sam-
ples collected after January 25, 2015, consent forms required spe-
cific language according to the National Institutes of Health’s
Genomic Data Sharing policy (see Web Resources).
Whole-Exome Sequencing Data Generation
All samples were sequenced at the Broad Institute of Harvard and
the Massachusetts Institute of Technology (MIT) on the Illumina
HiSeq X platform, with the use of 151 bp paired-end reads. Exome
capture was performed with Illumina Nextera Rapid Capture
Exomes or TruSeq Rapid Exome enrichment kit (target size
38 Mb), except for three control cohorts (MIGen ATVB, MIGen
Ottawa, and Swedish SCZ controls) for which the Agilent
SureSelect Human All Exon Kit was used (target size 28.6 Mb–
33 Mb). Sequence data in the form of BAM files were generated
via the Picard data-processing pipeline and contained well-cali-
brated reads aligned to the GRCh37 human genome reference.
Samples across projects were then jointly called via the Genome
Analysis Toolkit (GATK) best-practice pipeline31 for data harmoni-
zation and variant discovery. This pipeline detected single-nucleo-
tide variants (SNVs) and small insertion or deletion (indel) variants
from exome sequence data.
Quality Control
Variants were pre-filtered so that only those passing the GATK
VQSR (variant quality score recalibration) metric and those lying
outside of low-complexity regions remained.32 Genotypes with9
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allele balance >0.8 or <0.2 were set to missing. To control for
capture platform difference, we retained variants that resided in
GENCODE coding regions where 80% of Agilent and Illumina-
sequenced samples show at least 10-3 coverage. This resulted
in the removal of 50% of the called sites (23% of the total
coding variants and 97% of the total non-coding variants) but
effectively reduced the call rate difference between cases and
controls (Figure S1). To further identify potential false positive
sites due to technical variation, we performed single-variant
association tests (for variants with a minor-allele frequency
[MAF] >0.001) among the controls, treating one platform as the
pseudo-case group with adjustment for sex and the first ten prin-
cipal components (PCs). We removed variants that were signifi-
cantly associated with capture labels (p value < 0.05). We also
excluded variants with a call rate <0.98, case-control call-rate
difference >0.005, or Hardy-Weinberg Equilibrium (HWE) test
p value <13106 on the basis of the combined case and control
cohort.
Samples were excluded if they had a low average call rate
(<0.98), low mean sequence depth (<30; Figure S2), low mean
genotype quality (<85), high freemix contamination estimate
(>0.04), or high percent chimeric reads (>1.4%). We performed
a series of principal-component analyses (PCAs) to identify ances-
tral backgrounds and to control for population stratification; we
kept only individuals of European (EUR) ancestry classified by
Random Forest with 1000 Genomes data (Figure S3). Within the
EUR population, we removed controls not well matched with
cases on the basis of the top two PCs, and we removed individuals
with an excessive or a low count of synonymous singletons—a
number that increases with the north-to-south axis (Figure S4).
We also removed one sample from each pair of related individuals
(proportion identity by descent >0.2), and we removed those
whose genetically imputed sex was ambiguous or did not match
with self-reported sex. Outliers (>4 SD from the mean) of transi-
tion/transversion ratio, heterozygous/homozygous ratio, or inser-
tion/deletion ratio within each cohort were further discarded
(Figures S5–S7). At the phenotype level, we removed individuals
with epilepsy phenotype to be determined or marked as
‘‘excluded’’ from further review.
The number of variant and sample dropouts at each step is
detailed in Tables S3 and S4.Variant Annotation
Annotation of variants was performed with Ensembl’s Variant Ef-
fect Predictor (VEP)33 for human genome assemble GRCh37. On
the basis of the most severe consequence, we used relevant terms
and SnpEff34 impact to define four mutually exclusive functional
classes of variants (Table S5): protein-truncating variant (PTV),
damaging missense variant (predicted by PolyPhen-2 and sorting
intolerant from tolerant [SIFT]), benign missense variant (pre-
dicted by PolyPhen-2 and SIFT), and synonymous variant.
To further discriminate those missense variants that were most
likely deleterious from benign missense variants, we applied an
in silico missense deleteriousness predictor (missense badness,
PolyPhen-2, and regional constraint [MPC] score)35 that leverages
regional constraint information to annotate a subset of missense
variants that are highly deleterious (MPC R 2). The MPC R 2
group accounts for a small proportion of the total damaging and
benign missense variants annotated by PolyPhen-2 and SIFT.
Because many of our control samples were obtained from externalThedatasets used in the Exome Aggregation Consortium (ExAC)36
(Table S2), we used the DiscovEHR cohort—an external popula-
tion allele frequency reference cohort that contains 50,726
whole-exome sequences from a largely European and non-
diseased adult population37—to annotate whether a variant is ab-
sent in the general population (Figure S8).Gene-Set Burden Analysis
To estimate the excess of rare, deleterious protein-coding variants
in individuals with epilepsy, we conducted burden tests across the
entire exome, for biologically relevant gene sets, and at the indi-
vidual gene level. We focused on two definitions of ‘‘ultra-rare’’
genetic variants (URVs) for the primary analyses: (1) variants
not seen in the DiscovEHR database and observed only once
among the combined case and control test cohort (allele count
[AC] ¼ 1) or (2) variants absent in DiscovEHR and observed
no more than three times in the test cohort (AC % 3). These
URVs have been observed previously24,38 and in our study to
contain the strongest burden of deleterious pathogenic variants
compared to less-stringent allele frequency thresholds (Figures
S9 and S10). We performed these case-control comparisons sepa-
rately for each of the three primary epilepsy disorders (DEEs,
GGE, and NAFE) and again for all epilepsy-affected individuals
combined.
We implemented gene-set burden tests by using logistic regres-
sion to examine the enrichment of URVs in individuals with
epilepsy versus controls. We performed the test by regressing
case-control status on certain classes of URVs aggregated across a
target gene set in an individual and adjusting for sex, the top
ten PCs, and exome-wide variant count. This analysis tested the
burden of URVs separately for five functional coding annotations:
synonymous, benign missense as predicted by PolyPhen-2 and
SIFT, damaging missense as predicted by PolyPhen-2 and SIFT,
PTVs, and missense with MPCR 2 (Table S5). To help determine
whether our burden model was well calibrated, we used synony-
mous substitutions as a negative control where significant burden
effects would more likely indicate insufficient control of popula-
tion stratification or exome-capture differences. The inclusion
of overall variant count as a covariate—which tracks with
ancestry—made our test conservative but allowed for better con-
trol of residual population stratification not captured by PCs and
effectively reduced inflation of signals in synonymous variants
(Figure S11). We collected and tested 11 different gene sets,
including constrained genes that are intolerant to loss-of-function
(LoF) mutations (pLI > 0.9 and pLI > 0.99539) or missense varia-
tion (mis-Z > 3.0939), brain-enriched genes that are expressed at
a level more than 2-fold greater in brain tissues than in other tis-
sues according to Genotype-Tissue Expression Consortia (GTEx)
data,40 and genes reported to be associated with epilepsy in a
dominant fashion10,24 or with epilepsy-related mechanisms25
(Table S6).Because, unlike the gene-based burden tests, most of
the gene-set tests were not independent, for multiple testing we
used a false discovery rate (FDR) correction that accounted for
the number of functional categories (five), gene sets (11), and
epilepsy phenotypes (four), totaling 220 tests, and defined a signif-
icant enrichment at FDR < 0.05.Gene-Based Collapsing Analysis
For gene-based tests, we restricted our testing to deleterious URVs
annotated as PTVs, missense variants with MPCR 2, or in-frame
insertions and deletions. For each gene, individuals who eachAmerican Journal of Human Genetics 105, 1–16, August 1, 2019 3
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carriers, and we used a two-tailed Fisher’s exact test (FET) to assess
whether the proportion of carriers among epilepsy subgroup
cases was significantly higher than among controls. Instead of
assuming a uniform distribution for p values under the null, we
generated empirical p values by permuting case-control labels
500 times, ordering the FET p values of all genes for each permu-
tation, and taking the average across all permutations to form a
rank-ordered estimate of the expected p value distribution. We
did this by modifying functions in the ‘‘QQperm’’ R package (see
Web Resources). To avoid potential false discoveries, we defined
a stringent exome-wide significance at a p value < 6.8 3 107
and used Bonferroni correction to account for 18,509 consensus
coding sequence genes tested and the four individual case-control
comparisons.
Considering that recessive pathogenic variants were implicated
in a number of epilepsy-associated genes, mostly identified from
individuals with a DEE phenotype,8 we conducted a secondary
gene-based FET by using a recessive model and comparing the pro-
portion of carriers that are homozygous for the minor allele be-
tween cases and controls. The recessive model was assessed for
PTVs, missense (MPC R 2) variants, and in-frame indels sepa-
rately. For this analysis, we did not restrict to non-DiscovEHR
variants, and we relaxed the allele frequency up to MAF < 0.01
to account for the sparse occurrences.
Additionally, to evaluate the contribution of low-frequency
deleterious variants to epilepsy risk, we explored the gene burden
of all protein-truncating and damagingmissense variants for those
that had an MAF <0.01 using SKAT41 and including sex and the
top ten PCs as covariates in the analysis. We performed the tests
with the default weighting scheme [dbeta(1,25)].Single-Variant Association
We estimated associations of common and low-frequency variants
(MAF > 0.001) with epilepsy by Firth’s method to perform logistic
regression and correcting for sex and the first ten PCs.
QC, annotation, and analysis were largely performed with Hail
(see Web Resources), open-source software for scalable genomic
data analysis, in conjunction with R (version 3.4.2).Results
Whole-Exome Sequencing, QC, and Sample Overview
We performed WES on an initial dataset of over 30,000 ep-
ilepsy-affected and control individuals. After stringent QC,
we identified a total of 9,170 individuals with epilepsy and
8,436 controls without reported neurological or neuropsy-
chiatric-related conditions; none of these individuals were
related, and all were of European descent. Among the indi-
viduals with epilepsy, 1,021 were diagnosed with a DEE,
3,108 with GGE, 3,597 with NAFE, and 1,444 with other
epilepsy syndromes (lesional focal epilepsy, febrile sei-
zures, and others). We carefully matched affected individ-
uals and controls on the basis of genetic ancestry to
eliminate the possibility that, as can occur in studies of in-
dividuals from differing ancestries, population stratifica-
tion or effects of variable MAF resolution would result in
false positive findings. Because there was a lack of cosmo-
politan controls from non-European populations, affected4 The American Journal of Human Genetics 105, 1–16, August 1, 201individuals who were identified from PCA and who had
non-European ancestry were removed. Furthermore, to
ensure that the distribution of rare variants was balanced
between cases and controls,42 we removed a subset of
cohorts that included only affected individuals or only
control individuals (from Sweden, Finland, Cyprus, and
Turkey) where the mean synonymous singleton count
that significantly deviated from the overall average
was the consequence of incomplete ancestry matching
(Figure S4). We called a total of 1,844,644 sites in 18,509
genes in the final dataset, comprising 1,811,325 SNVs
and 33,319 indels, 48.5% of which were absent in the
DiscovEHR database.37 Among the non-DiscovEHR sites,
85% were singletons (defined as only one instance of
that variant), and 99% had a minor AC not more than
three (equivalent to MAF % 0.01%; Figure S8); the
missense with MPC R 2 annotation accounted for 2.0%
of the total missense variants (5.5% of the damaging and
1.0% of the benign missense variants predicted by
PolyPhen-2 and SIFT). In our primary burden analyses,
we focused on the URVs that are unique to the 17,606
individuals under study and are seen either only once
(AC¼ 1) or nomore than three times (AC% 3) in our data-
set. These URVs were shown to confer the largest risk of ep-
ilepsy in comparison to singletons observed in DiscovEHR,
doubletons, or beyond (Figures S9 and S10). As previously
described, epilepsy enrichment signals diminished with an
increase in allele frequency.24
Enrichment of Ultra-Rare Deleterious Variants in
Constrained Genes in DEEs and GGE
We first tested the burden of singleton URVs for each epi-
lepsy subgroup, as well as for all epilepsy-affected individ-
uals combined, versus controls among gene sets collected
on the basis of current understanding and hypothesis of
epilepsy causation. These included genes under evolu-
tionary constraint, genes highly expressed in the brain,
genes previously associated with epilepsy, GABAA receptor
subunit-encoding genes, genes delineating GABAergic
pathways, genes encoding excitatory neuronal receptors,
and cation channel-encoding genes (Table S6). To evaluate
the burden in constrained genes, we defined ‘‘LoF-intol-
erant’’ genes as those with either a pLI score36 > 0.9
(3,488 genes) or separately a pLI score > 0.995 (1,583
genes), and we defined ‘‘missense-constrained’’ genes as
those with a missense Z score > 3.09 (1,730 genes).39
Genes marked by these specific cutoffs have been shown
to be extremely intolerant to LoF or missense variation
and thus help to identify specific classes of variants with
a higher burden in diseased individuals.36,43,44 We used a
version of the scores derived from the non-neuropsychi-
atric subset of the ExAC samples. Because some of our con-
trol cohorts are also in ExAC (Table S2), we restricted our
constrained gene burden tests to controls outside of the
ExAC cohort (n ¼ 4,042).
Consistent with a recent study that evaluated de novo
burden in autism,44 burden signals of PTVs were mostly9
Figure 1. Burden of Ultra-Rare Single-
tons in LoF-Intolerant Genes (pLI> 0.995)
This analysis was restricted to 4,042 non-
ExAC controls for comparison with indi-
viduals who have epilepsy. We focused on
‘‘ultra-rare’’ variants not observed in the
DiscovEHRdatabase. Significanceof associ-
ation was displayed in false discovery rate
(FDR)-adjusted p values; errors bars indi-
cated 95% confidence intervals (CIs) of
the corresponding odds ratios. Odds ratios
and 95% CIs were not multiplicity
adjusted. The five functional coding
annotations were defined as described in
Table S5. PTV denotes protein-truncating
variants; the ‘‘damaging missense’’ and
‘‘benign missense’’ categories were pre-
dicted by PolyPhen-2 and SIFT, and
‘‘damaging missense-MPC’’ was a group of
missense variants with amissense badness,
PolyPhen-2, and regional constraint (MPC)
score R2. From top to bottom are the re-
sults based on all epilepsies: DEEs, GGE,
and NAFE. Compared to controls (FDR <
0.05), individuals with epilepsy, except for
individualswithNAFE, carried a significant
excess of ultra-rare PTV and damaging
missense (MPCR 2) variants. PTV burden
was higher than missense (MPC R 2)
burden across epilepsy types.
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pLI > 0.9 (Figures S12 and S13). Focusing on pLI >
0.995 in the all-epilepsy case-control analysis, both pro-
tein-truncating and damaging missense (MPC35 R 2)
URVs in LoF-intolerant genes showed a mutational
burden with an odds ratio (OR) of 1.3 (FDR-adjusted
p value [adj.p] ¼ 1.6 3 104) and 1.1 (adj.p ¼ 0.039),
respectively. Breaking this down by epilepsy types, we
found a significant excess of these deleterious URVs
among individuals with DEEs (ORPTV ¼ 1.4, adj.pPTV ¼
0.013; ORMPC ¼ 1.2, adj.pMPC ¼ 0.019), as expected. This
enrichment was also seen in individuals with GGE at a
magnitude comparable to that in individuals with DEEs
(ORPTV ¼ 1.4, adj.pPTV ¼ 9.1 3 105; ORMPC ¼ 1.2,
adj.pMPC ¼ 5.5 3 103) but was not significant in individ-
uals with NAFE (ORPTV ¼ 1.2, adj.pPTV ¼ 0.062; ORMPC ¼
1.0, adj.pMPC ¼ 0.37; Figure 1). There was no evidence of
excess burden in synonymous URVs, suggesting that
enrichment of deleterious pathogenic variants was un-
likely to be the result of un-modeled population stratifica-
tion or technical artifact. Among in silico missense predic-
tors, MPC R 2 annotations consistently showed a higher
burden than those predicted by PolyPhen-2 and SIFT. The
burden among missense-constrained genes exhibited a
similar pattern: PTVs showed a higher burden in DEEs
than in GGE and NAFE (Figure S14). In addition, both
large gene sets were more enriched for PTVs than for
damaging missense variants.TheBurden in Candidate Genetic Etiologies Associated with
Epilepsy
Among URVs in previously reported genes associated with
epilepsy, we found an expected and pronounced difference
in the number of singleton protein-truncating URVs in
DEE-affected individuals relative to controls. PTVs were
associated with an increased DEE risk in 43 genes known
to carry mutations that cause dominant epilepsy disor-
ders24 (OR¼ 6.3, adj.p¼ 2.13 108), 50 known genes asso-
ciated with dominant DEE syndromes10 (OR ¼ 9.1, adj.p ¼
7.83 1011), and 33 genes with de novo burden in neurode-
velopmental disorders with epilepsy10 (OR ¼ 14.8, adj.p ¼
1.7 3 1012). Evidence for an excess of ultra-rare PTVs was
also observed in individuals with GGE, at an OR ranging
from 2 to 4. No enrichment of PTVs was observed among
people with NAFE (Figure 2A; Table S9). In contrast, the
burden of singleton missense (MPC R 2) URVs was more
pervasive across epilepsy types. In comparison to controls,
there was a 3.6-fold higher rate of these missense URVs in
established epilepsy-associated genes in individuals with
DEEs (adj.p ¼ 1.6 3 1010), a 2.3-fold elevation in individ-
uals with GGE (adj.p¼ 6.43 107), and a 1.9-fold elevation
in individuals with NAFE (adj.p ¼ 2.8 3 104).
Burden in Genes Encoding for Cation Channels and
Neurotransmitter Receptors
Among brain-enriched genes—those defined as genes
whose expression in brain tissues was at least 2-fold greaterAmerican Journal of Human Genetics 105, 1–16, August 1, 2019 5
Figure 2. Burden of Ultra-Rare Singletons Annotated as Protein-Truncating Variants or Damaging Missense (MPCR 2) Variants
‘‘Ultra-rare’’ variants (URVs) were defined as not observed in the DiscovEHR database. Gene sets were defined in Table S6 and the number
of genes was specified in the parenthesis. DEE stands for individuals with developmental and epileptic encephalopathies, GGE for ge-
netic generalized epilepsy, NAFE for non-acquired focal epilepsy, and EPI for all epilepsy; NDD-EPI genes are genes with de novo burden in
neurodevelopmental disorders with epilepsy. Asterisks indicate significance after FDR control (* for FDR-adjusted p value < 0.05, ** for
adjusted p value < 13 103, and *** for adjusted p value < 1 3 105). Effects were displayed in odds ratios with the corresponding 95%
confidence intervals (CIs).
(A) Protein-truncating variants (PTVs) were enriched in candidate epilepsy-associated genes for individuals with DEEs relative to other
epilepsy subgroups but did not show a strong signal in inhibitory, excitatory receptors, or voltage-gated cation channel genes.
(B) The burden of damaging missense (MPCR 2) variants, on the other hand, was stronger across these gene sets than was that of PTVs,
especially for GABAA receptor genes and genes involved in GABAergic pathways. Relative to other epilepsy types, individuals with NAFE
consistently showed the least burden of deleterious URVs. No enrichment was observed from excitatory receptors.
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GTEx data40—both protein-truncating and damaging
missense (MPC R 2) URVs were significantly enriched in
individuals with epilepsy versus controls, and themissense
burdenwasmuchhigher than the PTV burden (Figure S15).
We then investigated the burden in four smaller gene sets
previously implicated as mechanisms driving the etiology
of epilepsy; these included 19 genes encoding GABAA re-
ceptor subunits, 113 genes involved in GABAergic path-
ways, 34 genes encoding excitatory receptors (ionotropic
glutamate receptor subunits and nicotinic acetylcholine
receptor subunits), and 86 voltage-gated cation channel
genes (e.g., sodium, potassium, calcium—full list in Table
S6).25 We discovered that, relative to that of damaging
missense variants, the distribution of PTVs inmost of these
gene sets did not differ significantly between epilepsy cases
and controls (Figure 2A; Table 1). The PTV signals that re-
mained significant after FDR correction included, for indi-
viduals with a DEE, an increased burden in GABAergic
pathway genes and voltage-gated cation channels, and
noticeably for individuals with GGE, an increased burden6 The American Journal of Human Genetics 105, 1–16, August 1, 201in the inhibitory GABAA receptors (OR ¼ 4.8, adj.p ¼
0.021). No PTV burden was detected for individuals
with NAFE. In contrast, the enrichment of missense
(MPC R 2) URVs was more extensive in these gene sets
across all epilepsy-to-control comparisons (Figure 2A;
Table 1). The burden of these damaging missense patho-
genic variants was seen in GABAA receptor genes
(ORDEE ¼ 3.7, adj.pDEE ¼ 0.028; ORGGE ¼ 3.8, adj.pGGE ¼
1.4 3 103; ORNAFE ¼ 2.7, adj.pNAFE ¼ 0.039), GABAergic
pathway genes (ORDEE ¼ 2.6, adj.pDEE ¼ 4.7 3 105;
ORGGE ¼ 1.9, adj.pGGE ¼ 9.9 3 104; ORNAFE ¼ 1.4,
adj.pNAFE ¼ 0.11), and voltage-gated cation channel genes
(ORDEE ¼ 2.1, adj.pDEE ¼ 1.7 3 103; ORGGE ¼ 1.5,
adj.pGGE ¼ 0.023; ORNAFE ¼ 1.4, adj.pNAFE ¼ 0.081). How-
ever, no enrichment was detected in genes encoding excit-
atory receptors. For individuals with NAFE, the burden
signals were consistently the weaker across gene sets
compared than in individuals with the other epilepsy phe-
notypes. None of the gene sets was enriched for putatively
neutral variation, except for a slightly elevated synony-
mous burden in GABAA receptor genes (Table S9). These9
Table 1. Enrichment of Ultra-Rare Protein-Truncating or Damaging Missense (MPC R 2) Singletons in Epilepsy
Epilepsy Type
Carriers (N)
OR 95% CI p Value FDR-Adjusted pAffected Individuals Controls
Dominant Epilepsy Disorders (43)
PTV (95)
EPI 67 27 2.37 (1.50–3.74) 2.0310-4 1.2310-3
DEE 24 27 6.28 (3.48–11.3) 1.0310-9 2.1310-8
GGE 22 27 2.33 (1.32–4.11) 3.6310-3 1.4310-2
NAFE 15 27 1.38 (0.72–2.66) 3.4310-1 4.7310-1
EPI 235 98 2.21 (1.74–2.81) 1.1310-10 2.8310-9
MPC R 2 (335)
DEE 47 98 3.60 (2.50–5.19) 5.0310-12 1.6310-10
GGE 85 98 2.31 (1.71–3.12) 4.4310-8 6.4310-7
NAFE 80 98 1.91 (1.41–2.60) 3.3310-5 2.8310-4
Dominant DEE Syndromes (50)
PTV (89)
EPI 68 21 3.00 (1.82–4.95) 1.8310-5 1.6310-4
DEE 27 21 9.13 (4.93–16.9) 2.1310-12 7.8310-11
GGE 25 21 3.57 (1.95–6.54) 3.7310-5 3.0310-4
NAFE 10 21 1.05 (0.48–2.29) 9.1310-1 9.3310-1
EPI 224 101 2.05 (1.61–2.60) 6.5310-9 1.2310-7
MPC R 2 (327)
DEE 54 101 4.20 (2.97–5.95) 6.0310-16 1.3310-13
GGE 85 101 2.22 (1.64–3.00) 2.0310-7 2.6310-6
NAFE 63 101 1.42 (1.02–1.97) 3.7310-2 8.8310-2
Neuro-Developmental Disorders with Epilepsy (33)
PTV (63)
EPI 49 14 3.22 (1.75–5.90) 1.6310-4 9.9310-4
DEE 29 14 14.77 (7.4–29.49) 2.3310-14 1.7310-12
GGE 14 14 2.86 (1.32–6.17) 7.7310-3 2.7310-2
NAFE 4 14 0.75 (0.24–2.34) 6.2310-1 7.2310-1
MPC R 2 (215)
EPI 149 65 2.11 (1.57–2.84) 9.4310-7 1.1310-5
DEE 36 65 4.30 (2.81–6.57) 1.8310-11 5.1310-10
GGE 54 65 2.18 (1.50–3.17) 4.2310-5 3.2310-4
NAFE 41 65 1.43 (0.96–2.15) 8.0310-2 1.6310-1
GABAA Receptors (19)
PTV (17)
EPI 12 5 1.99 (0.69–5.74) 2.0310-1 3.2310-1
DEE 1 5 2.25 (0.25–20.2) 4.7310-1 6.0310-1
GGE 9 5 4.81 (1.57–14.7) 5.9310-3 2.1310-2
NAFE 1 5 0.37 (0.04–3.27) 3.7310-1 5.0310-1
(Continued on next page)
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Table 1. Continued
Epilepsy Type
Carriers (N)
OR 95% CI p Value FDR-Adjusted pAffected Individuals Controls
MPC R 2 (62)
EPI 49 13 3.25 (1.74–6.07) 2.1310-4 1.2310-3
DEE 7 13 3.65 (1.39–9.54) 8.3310-3 2.8310-2
GGE 21 13 3.81 (1.86–7.81) 2.5310-4 1.4310-3
NAFE 15 13 2.67 (1.23–5.77) 1.3310-2 3.9310-2
GABAergic Pathway (113)
PTV (127)
EPI 81 44 1.58 (1.10–2.28) 1.4310-2 4.4310-2
DEE 16 44 2.46 (1.37–4.39) 2.4310-3 1.0310-2
GGE 28 44 1.60 (0.99–2.57) 5.3310-2 1.1310-1
NAFE 24 44 1.19 (0.73–1.95) 4.9310-1 6.1310-1
MPC R 2 (287)
EPI 185 101 1.73 (1.35–2.22) 1.6310-5 1.6310-4
DEE 34 101 2.62 (1.74–3.95) 4.5310-6 4.7310-5
GGE 68 101 1.86 (1.35–2.56) 1.6310-4 9.9310-4
NAFE 58 101 1.40 (1.00–1.95) 4.7310-2 1.1310-1
Excitatory Receptors (34)
PTV (54)
EPI 22 32 0.66 (0.37–1.15) 1.4310-1 2.5310-1
DEE 3 32 0.71 (0.21–2.35) 5.7310-1 6.7310-1
GGE 11 32 1.10 (0.54–2.23) 8.0310-1 8.4310-1
NAFE 5 32 0.44 (0.17–1.15) 9.5310-2 1.8310-1
MPC R 2 (80)
EPI 47 33 1.28 (0.81–2.02) 2.9310-1 4.3310-1
DEE 9 33 1.76 (0.81–3.81) 1.5310-1 2.6310-1
GGE 12 33 0.91 (0.46–1.79) 7.8310-1 8.3310-1
NAFE 20 33 1.50 (0.84–2.65) 1.7310-1 2.8310-1
Voltage-Gated Cation Channels (86)
PTV (163)
EPI 100 63 1.45 (1.05–2.01) 2.5310-2 7.0310-2
DEE 18 63 2.11 (1.21–3.66) 8.2310-3 2.8310-2
GGE 31 63 1.38 (0.88–2.16) 1.6310-1 2.7310-1
NAFE 30 63 1.15 (0.73–1.81) 5.5310-1 6.7310-1
MPC R 2 (329)
EPI 206 121 1.51 (1.20–1.90) 4.7310-4 2.4310-3
DEE 34 121 2.08 (1.40–3.10) 3.1310-4 1.7310-3
GGE 73 121 1.52 (1.12–2.07) 6.6310-3 2.3310-2
NAFE 74 121 1.39 (1.03–1.88) 3.1310-2 8.1310-2
This analysis compared the burden of deleterious pathogenic variants between cases and controls using logistic regression and adjusting for sex, the first ten prin-
cipal components, and overall variant count. FDR correction was based on a full list of burden tests shown in Table S9. Tested epilepsy types included all epilepsies
(EPI; n¼ 9,170), developmental and epileptic encephalopathies (DEE; n¼ 1,021), genetic generalized epilepsy (GGE; n¼ 3,108), and non-acquired focal epilepsy
(NAFE; n¼ 3,597). All were compared against 8,436 control samples. Figure 2 shows the enrichment pattern of PTVs and MPCR 2 variants across the seven gene
sets listed here.
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Figure 3. Gene Burden for Individuals Diagnosed with Develop-
mental and Epileptic Encephalopathies, Genetic Generalized
Epilepsy, or Non-Acquired Focal Epilepsy
This analysis focused on ultra-rare (non-DiscovEHR) singleton var-
iants annotated as protein-truncating variants (PTVs), damaging
missense variants (MPCR 2), or in-frame insertions and deletions
and used Fisher’s exact test (FET) to identify genes with a differen-
tial carrier rate of these ultra-rare deleterious variants in individ-
The
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tion in GABAA receptor genes conferred a significant risk to
GGE25 and together implicate the relative importance and
involvement of damaging missense variants in abnormal
inhibitory neurotransmission in both severe and less se-
vere forms of epilepsy.
For gene sets other than the three lists of previously asso-
ciated genes (Table S6; 74 non-overlapping genes in total),
we evaluated the residual burden of URVs after correcting
for events in the 74 known genes. For the gene sets of
cation channel and neurotransmitter receptor genes, the
adjusted burden signals of singleton deleterious URVs
was largely reduced, although some weak associations re-
mained in GABAA receptor-encoding or GABAergic genes
among individuals with DEEs or GGE. For the larger gene
groups of constrained genes and brain-enriched genes,
burden signals were attenuated, but many remained
significant, especially the strong enrichment of missense
MPCR 2 variants in brain-enriched genes across all three
classes of epilepsy (Figure S16). These findings suggest that
although most gene burden is driven by previously identi-
fied genes, more associations could be uncovered with
larger sample sizes.
Gene-Based Collapsing Analysis Recaptures Known
Genes Associated with DEEs
For gene discovery, because both protein-truncating and
damaging missense (MPC R 2) URVs showed an elevated
burden in epilepsy cases, we aggregated both together as
deleterious pathogenic variants along with in-frame inser-
tions and deletions in our gene-collapsing analysis. This
amassed to a total of 46,917 singleton URVs and
52,416 URVs with AC % 3. Surprisingly, for individuals
diagnosed with DEEs, we re-identified several of the estab-
lished candidate genes associated with DEEs as top associ-
ations (Figure 3A). Although screening was not performed
systematically, using clinical gene panels prior to enroll-
ment produced negative results for many participants
with DEEs (Table S7). According to the results from
singleton URVs, SCN1A (MIM: 182389) was the only
gene that reached exome-wide significance (OR ¼ 18.4,
p ¼ 5.8 3 108); other top-ranking known genes included
NEXMIF ([MIM: 300524] previously known as KIAA2022;
OR > 99, p ¼ 1.6 3 106), KCNB1 ([MIM: 600397] OR ¼
20.8, p ¼ 2.5 3 104), SCN8A ([MIM: 600702] OR ¼ 13.8,
p ¼ 6.1 3 104), and SLC6A1 ([MIM: 137165] OR ¼ 11.1,
p ¼ 3.6 3 103) (Table S11). Some carriers of deleterious
URVs in lead genes were affected individuals with normal
results for gene panel testing; for example, these included
two out of the three carriers of qualifying URVs for PURAuals with epilepsy in comparison to controls. Exome-wide signifi-
cance was defined by a p value < 6.8 3 107 after Bonferroni
correction (see Materials and Methods). Only SCN1A achieved
exome-wide significance for individuals with developmental and
epileptic encephalopathies (DEEs). Panels refer to individuals diag-
nosed with (A) developmental and epileptic encephalopathies, (B)
genetic generalized epilepsy, and (C) non-acquired focal epilepsy.
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This is primarily because gene panels ordered for a partic-
ular diagnosis usually do not screen all of the genes
commonly implicated in DEEs (e.g., one of the carriers of
qualifying URVs in KCNB1 was diagnosed with West syn-
drome [MIM: 308350] and screened with a customized
panel that did not include KCNB1). Overall, more than
50 different gene panels were used across sample-contrib-
uting sites, which adds to the heterogeneity in screening
procedures and interpretation. The gene burden results
held up when URVs with AC % 3 were considered and
these results often showed even stronger associations;
two other well-studied genes, STXBP1 ([MIM: 602926]
OR ¼ 13.3, p ¼ 1.4 3 105) and WDR45 ([MIM: 300526]
OR > 49, p ¼ 1.2 3 103), emerged on top, and both of
these have been implicated in DEEs and developmental
disorders (Table S12).
Channel and Transporter Genes Implicated in GGE and
NAFE
When evaluating gene burden in the GGE and NAFE epi-
lepsy subgroups, we did not identify any genes of
genome-wide significance. However, several candidate
genes previously associated with epilepsy made up the
lead associations; such genes included ion channel and
transporter genes, mutations of which are known to cause
rare forms of epilepsy. For the GGE case-control analysis in
singleton deleterious URVs, the lead associations included
four previously associated genes (EEF1A2 [MIM: 602959],
OR ¼ 32, p ¼ 3.8 3 104; GABRG2 [MIM: 137164], OR ¼
19.0, p ¼ 6.2 3 104; SLC6A1 [MIM: 616421], OR ¼ 7.3,
p ¼ 2.0 3 103; and GABRA1 [MIM: 137160], OR ¼ 9.5,
p ¼ 2.2 3 103), and two genes (CACNA1G [MIM:
604065], OR ¼ 9.1, p ¼ 2.5 3 104 and UNC79 [MIM:
616884], OR ¼ 19.0, p ¼ 6.2 3 104) that were not previ-
ously linked to epilepsy but are both highly expressed in
the brain and under evolutionary constraint (Figures 3B;
Table S13). Although evidence has been mixed, CACNA1G
was previously implicated as a potential susceptibility gene
associated with GGE in mutational analysis45 and was
reported to modify mutated sodium channel (SCN2A
[MIM: 182390]) activity in epilepsy.46 UNC79 is an essen-
tial part of the UNC79-UNC80-NALCN (MIM: 612636,
MIM: 611549) channel complex that influences neuronal
excitability by interacting with extracellular calcium
ions,47 and this channel complex has been previously asso-
ciated with infantile encephalopathy.48 Notably, all of
these lead genes were more enriched for damaging
missense (MPC R 2) than for protein-truncating URVs
despite the lower rate of MPC R 2 variants relative to
PTVs (Table S13).
For individuals with NAFE, the analysis of singleton
deleterious URVs identified LGI1 (MIM: 604619) and
TRIM3 (MIM: 605493) as the top two genes carrying a
disproportionate number of deleterious URVs; however,
neither reached exome-wide significance (OR > 32,
p ¼ 2.1 3 104). GABRG2, a lead association in individuals10 The American Journal of Human Genetics 105, 1–16, August 1, 20with GGE, was among the top ten most enriched genes,
along with two brain-enriched, constrained genes (PPFIA3
[MIM: 603144], OR¼ 8.2, p¼ 4.23 103 and KCNJ3 [MIM:
601534], OR ¼ 16.4, p ¼ 1.2 3 103). GABRG2 has previ-
ously been reported to show an enrichment of variants
compared to controls in a cohort of individuals with
Rolandic epilepsy ([MIM: 245570, 300643] childhood epi-
lepsy with centrotemporal spikes) or related phenotypes,
the most common group of focal epilepsies of child-
hood.49 Two other genes previously associated with epi-
lepsy, DEPDC5 (MIM: 614191) and SCN8A (both OR ¼
5.5, p ¼ 0.01), were among the top 20 associations (Figures
3C; Table S14). LGI1 and DEPDC5 are established genes
associated with focal epilepsy, and DEPDC5 was the
only hit of exome-wide significance in the Epi4K WES
study for familial NAFE cases.24 TRIM3 has not been previ-
ously implicated in epilepsy, but evidence from a study
involving a mouse model implicates it in regulation of
GABAA receptor signaling and thus in modulation of
seizure susceptibility.50 The single-gene burden for both
GGE and NAFE remained similar when URVs with an allele
count up to AC% 3 were considered (Tables S14 and S16).
Gene burden tests collapsing all epilepsy phenotypes reca-
pitulated the lead genes in each of the subgroup-specific
analyses, but none of the genes achieved exome-wide sig-
nificance (Tables S17 and S18). It is worth noting that
some of the genes were enriched for deleterious URVs
among the controls; this is clearly driven by non-neuro-
psychiatric disease ascertainment for many of the available
controls (e.g., LDLR [MIM: 606945] in Table S17; most con-
trol carriers were individuals with cardiovascular diseases
from the MIGen cohorts in Table S2). Thus, these should
not be interpreted as potential protective signals associated
with epilepsy.
Recessive Model, SKAT Gene Test, and Single-Variant
Association
The secondary gene-based test of a recessive model did not
identify genes that differed significantly in the carrier rate
of homozygous deleterious variants between epilepsy-
affected individuals and controls (Table S19). Even if we
considered variants up to MAF < 0.01, for most of the
lead genes, only one case carrier was identified. For the
DEE cohort, these genes included previously implicated
recessive genes, such as ARV1 (MIM: 611647), BRAT1
(MIM: 614506), and CHRDL1 (MIM: 300350)51 with a ho-
mozygous PTV and OPHN1 (MIM: 300127)51 with a reces-
sive missense (MPCR 2) variant (Table S19A). For the GGE
and NAFE cohorts, in the lead gene associations, a few
studied recessive epilepsy-associated genes were also
observed, such as SLC6A851 ([MIM: 300036] a homozygous
PTV) for GGE (Table S19B), and SLC6A8 (a homozygous
missense MPC) and SYN151 ([MIM: 313440] a homozy-
gous PTV) for NAFE (Table S19C). One GGE-affected indi-
vidual was found to be homozygous for an in-frame dele-
tion on CHD2 (MIM: 602119), a gene previously reported
to carry autosomal dominant pathogenic variants in19
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that an even larger cohort will be needed to clearly identify
recessive risk variants for different groups of epilepsy.
Beyond URVs, we used SKAT to study the contribution of
low-frequency deleterious variants (MAF < 0.01) to epi-
lepsy risk. Top associations for individuals with DEEs
included known genes such as missense-enriched STXBP1
(p ¼ 9.3 3 109), KCNA2 ([MIM: 176262] p ¼ 1.0 3 105;
Figure S18), PTV-enriched NEXMIF (p ¼ 7.1 3 108), and
SCN1A (p ¼ 3.9 3 104; Figure S19). However, no signifi-
cant gene enrichment was observed in the GGE and
NAFE cohorts or when all epilepsy-affected individuals
were combined. The tests for PTVs and missense variants
with MPC R 2 were mostly underpowered as a result of
sparse observations (Figures S18 and S19). No individual
low-frequency variant (MAF > 0.001) was significantly
associated with overall epilepsy or with any of the studied
epilepsy phenotypes (Figure S20). The primary gene-based
test results and single-variant associations are available on
our Epi25 WES browser (see Web Resources).Discussion
In this, the largest exome study of epilepsies to date, we
show that ultra-rare deleterious coding variation—varia-
tion absent in a large population-based exome data-
base—is enriched across the severity spectrum for epilepsy
syndromes when individuals with these syndromes are
compared to ancestrally matched controls. When all genes
were considered in the tested gene sets, PTVs showed a
more significant signal than did missense variants with
an MPC R 2, and enrichment in deleterious URVs was
more pronounced in individuals diagnosed with DEEs
and GGE than in those diagnosed with NAFE. Although
no single gene surpassed exome-wide statistical signifi-
cance to be associated with GGE or NAFE, specific gene
sets that had previously been associated with epilepsy or
with encoding biologically interesting entities showed a
clear enrichment of deleterious URVs. Specifically, we
observed a significant excess of deleterious URVs in con-
strained genes, established epilepsy-associated genes, and
GABAA receptor subunit genes, a larger group of genes
delineating the GABAergic pathway, and also in all
cation-channel-encoding genes. Our results thus support
the concept that defects in GABAergic inhibition underlie
various forms of epilepsy. The epilepsy-associated excess of
deleterious URVs in our studymost likely comprises signals
from both inherited and de novo variants; these de novo
variants were enriched by the restriction of variant
inclusion to a combination of study-specific singletons
and by their absence in a population reference cohort
(DiscovEHR).38,43 These findings, based on a more than
5-fold increase in sample size over previous exome-
sequencing studies,24–26,52 clearly support observations
that have been hypothesized for GGE and NAFE from
studies of rare, large monogenic families and confirmThe Athat the same genes are relevant in both settings. Thus, a
further increase in sample size will continue to unravel
the complex genetic architecture of GGE and NAFE. The
evidence that URVs contribute, in part, to GGE and
NAFE is clear, but what remains unclear is the extent to
which the excess rate of URVs observed in individuals
with epilepsy is a consequence of a small subset of affected
individuals carrying highly penetrant mutations or a result
of URVs that confer risk but, instead of rising to the level of
Mendelian acting mutations, simply contribute to an over-
all polygenic risk for these syndromes. Interestingly, no
enrichment was seen in genes encoding the excitatory
glutamate and acetylcholine receptors. For GGE, this dif-
ference between variants in inhibitory versus excitatory re-
ceptor genes could be real: excitatory receptor variants
have not been shown so far in single subjects or families.
In NAFE, however, we suspect it is probably due to a lack
of power and/or genetic heterogeneity because genetic var-
iants in specific subunits of nicotinic acetylcholine and
NMDA receptors have been described extensively in
different types of non-acquired familial focal epilepsies.53
Notably, our overall finding of a mild to moderate
burden of deleterious coding URVs in NAFE (Figures 1
and 2) contrasts with results reported in the Epi4K WES
study, where the familial NAFE cohort showed a strong
enrichment signal of ultra-rare functional variation in
genes commonly implicated in epilepsy and ion-channel
genes.24 In addition, our findings for GGE showed a ge-
netic risk comparable to or even stronger than that in
the Epi4K familial GGE cohort. The strong signal in our
GGE cohort most likely reflects the larger sample size,
whereas the weaker signal in our NAFE cohort is most
likely due to differences in patient ascertainment. In
Epi4K, the cohort was deliberately enriched with familial
cases, most of whom had an affected first-degree relative
and were ascertained in sibling or parent-child pairs or
multiplex families, and familial NAFE is relatively uncom-
mon. In the Epi25 collaboration, a positive family history
of epilepsy was not a requirement, and only 9% of individ-
uals with DEEs, 12% of those with GGE, and 5% of those
with NAFE had a known affected first-degree relative.
Removing these familial cases led to no change in gene-
set burden (Figure S17) and to a slightly attenuated associ-
ation for some of the lead genes in the GGE and NAFE
cohorts (Table S20). Indeed, our results were consistent
with those from the Epi4K sporadic NAFE cohort, where
no signals of enrichment were observed.24,54 This differ-
ence might reflect the substantial etiological and genetic
heterogeneity of epilepsy even within subgroups, espe-
cially in NAFE. In particular, the dramatically weaker ge-
netic signals, per sample, observed in individuals with
NAFE studied here in comparison with those in the previ-
ous Epi4K study illustrate a pronounced difference in the
genetic signals associated with familial and non-familial
NAFE. The reasons for this striking difference remain to
be elucidated. Our comparisons of GGE and NAFE showed
a larger genetic burden from URVs for GGE relative tomerican Journal of Human Genetics 105, 1–16, August 1, 2019 11
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ical syndromes within each class and should not be viewed
as conclusive. On the other hand, in the latest GWAS of
common epilepsies, which was comprised of 15,212 cases
and 29,677 controls from the ILAE Consortium,20 fewer
GWAS hits were discovered, and less heritability was ex-
plained by common genetic variation for the focal epilepsy
cohort (9.2%) compared to the GGE cohort (32.1%),
suggesting that current evidence from both common and
rare-variant studies is converging on a larger genetic
component underlying the etiology of non-familial cases
of GGE relative to NAFE, as originally postulated.
We found that ultra-rare missense variants with an MPC
score35 R 2 (2.0% of missense variants) were enriched in
individuals with epilepsy at an effect size approaching
the results from PTVs in the investigated gene groups.
For GGE and NAFE, the burden of these missense variants
(MPC R 2) was even more prominent than the burden of
PTVs in known genes associated with epilepsy and
GABAergic genes (Figure 2). At the gene level, some
of the most commonly implicated channel genes (e.g.,
GABRG2, CACNA1G) carried a higher number of missense
variants (MPCR 2) than PTVs in people with epilepsy. For
instance, in the gene-based collapsing analysis considering
all epilepsies, 15 GABRG2 pathogenic variants were found
in epilepsy-affected individuals (including seven with GGE
and sevenwith NAFE; Tables S13, S15, and S17) versus only
one pathogenic variant in controls; among the case-spe-
cific pathogenic variants, one was a splice-site mutation,
and the other 14 were all missense variants (MPC R 2)
(Figure S21) that linked to an impaired channel function.
This is in line with findings from a recent exome-wide
study of 6,753 individuals with neurodevelopmental disor-
der with and without epilepsy;10 that study detected an as-
sociation of missense de novo variants with the presence of
epilepsy, particularly when considering only ion-channel
genes. An association of missense variants, rather than
PTVs, with disease points to a pathophysiological mecha-
nism of protein alteration (e.g., gain-of-function or domi-
nant-negative effects) rather than haploinsufficiency, but
ultimately, only functional tests can elucidate these mech-
anisms. A recent study on the molecular basis of six de novo
missense variants in GABRG2 identified in DEEs reported
that the overall inhibitory function of GABRG2 was
reduced as a result of decreased cell surface expression or
GABA-evoked current amplitudes, suggesting GABAergic
disinhibition as the underlying mechanism.55 Surpris-
ingly, two of those recurrent de novo missense variants
(c.316G>A [p.Ala106Thr] and c.968G>A [p.Arg323Gln])
were seen in two GGE-affected individuals in our study,
and another recently reported variant in GABRB2
(c.946G>A [p.Val316Ile]) also occurred both de novo in
DEEs56 and as an inherited variant in a GGE family
showing a loss of receptor function.25 This suggests that
changes in protein function from the same missense path-
ogenic variant might contribute not only to severe epi-
lepsy syndromes but also to epilepsy phenotypes with12 The American Journal of Human Genetics 105, 1–16, August 1, 20milder presentations, similar to what is known about vari-
able expressivity in large families carrying GABRG2 vari-
ants.53,57–59 Reduced receptor function due to GABRG2
variants has been also been shown previously49,59 for
childhood epilepsy with centrotemporal spikes, symptoms
that belong to the NAFE group in this study. Moving for-
ward, discovering how variant-specific perturbations of
the neurotransmission and signaling system in a gene
can link to a spectrum of epilepsy syndromes will require
in-depth functional investigation.
Although we have increased the sample size from the
Epi4K and EuroEPINOMICS WES studies for both GGE
and NAFE subgroups by more than 5-fold, the phenotypic
and genetic heterogeneity of these less-severe forms of
epilepsy—on par with other complex neurological and
neuropsychiatric conditions—will require many more
samples to achieve statistical power for identifying
exome-wide significant genes. We estimated that at least
8,000 cases and 20,000 controls would be required in order
for some of the lead genes from the GGE and NAFE cohorts
to exome-wide significance (Table S8). Furthermore,
although we implemented stringent QC to effectively con-
trol for the exome capture differences between individuals
with epilepsy and controls, this concomitantly resulted in
a loss of a substantial number of the called sites and
reduced our detection power to identify associated vari-
ants. As sample sizes grow, the technical variation across
projects and sample collections will remain a challenge
in large-scale sequencing studies that rely on a global
collaborative effort.
With this, the largest epilepsy WES study to date, we
demonstrated a strong replicability of existing gene find-
ings in an independent cohort. GABAA receptor genes
affected by predicted-pathogenic missense variants were
enriched across the three subgroups of epilepsy. An
ongoing debate in epilepsy genetics is the degree to which
generalized and focal epilepsies segregate separately and
whether their genetic determinants are largely distinct or
sometimes shared.4,22 Although clinical evidence for gen-
eral separation of pathophysiological mechanisms in these
two forms is strong, andmost monogenic epilepsy families
have either generalized or focal syndromes, the distinction
is not absolute. Here, the finding of rare variants in GABAA
receptor genes in both forms adds weight to the case for
shared genetic determinants.
Our results suggest that clinical presentations of GGE
and NAFE with complex inheritance patterns have a com-
bination of both common and rare genetic risk variants.
The latest ILAE epilepsy GWAS of over 15,000 affected in-
dividuals and 25,000 controls identified 16 genome-wide
significant loci for common epilepsies,20 mapped these
loci to ion-channel genes, transcriptional factors, and
pyridoxine metabolism, and implicated these loci as hav-
ing a role in epigenetic regulation of gene expression in
the brain. A combination of rare and common genetic as-
sociation studies with large sample sizes, along with the
growing evidence from studies of copy-number variation19
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further decipher the genetic landscape of GGE and NAFE.
The ongoing effort of the Epi25 Collaborative is expected
to double the patient cohorts in upcoming years; the
goal is to elucidate shared and distinct gene discoveries
associated with severe and less-severe forms of epilepsy
and ultimately facilitatate precision medicine strategies
in the treatment of epilepsy.Accession Numbers
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